Atea and Roche get a Covid-19 antiviral warning
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
US backs another Covid-19 booster
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Unexpected win opens the way to an oral Covid antiviral
Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.
Covid-19 research efforts slow
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Roche takes the Tim-3 battle to Novartis
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
